Contrasting Standard BioTools (NASDAQ:LAB) and HeartSciences (NASDAQ:HSCS)

Standard BioTools (NASDAQ:LAB) and HeartSciences (NASDAQ:HSCS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Earnings & Valuation

This table compares Standard BioTools and HeartSciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$174.43 million	2.73	-$138.88 million	($0.34)	-3.65
HeartSciences	N/A	N/A	-$8.77 million	($6.88)	-0.46

HeartSciences has lower revenue, but higher earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Standard BioTools and HeartSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Standard BioTools	-86.06%	-20.89%	-15.98%
HeartSciences	N/A	-388.12%	-161.65%

Institutional & Insider Ownership

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 23.2% of Standard BioTools shares are held by company insiders. Comparatively, 1.8% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Standard BioTools and HeartSciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1	3	0	0	1.75
HeartSciences	1	0	1	0	2.00

Standard BioTools currently has a consensus target price of $1.35, indicating a potential upside of 8.87%. HeartSciences has a consensus target price of $9.20, indicating a potential upside of 191.14%. Given HeartSciences’ stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Standard BioTools.

Risk & Volatility

Standard BioTools has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, HeartSciences has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500.

Summary

HeartSciences beats Standard BioTools on 7 of the 13 factors compared between the two stocks.

About Standard BioTools

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

About HeartSciences

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.